Endonovo Therapeutics (OTC: ENDV) is a biotech company developing a bioelectronic approach to regenerative medicine. The company’s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating and preventing vital organ failure through the reduction of inflammation and the promotion of regeneration. Endonovo is initially concentrating on treating acute inflammatory conditions in the liver using this technology. Endonovo’s Cytotronics™ platform is designed to expand and optimize the therapeutic potential of stem cells and for the production of fully human biomolecules. The company is initially concentrating on the creation of next generation cell therapies that have been enhanced using bioelectronics for the treatment of Graft-Versus-Host Disease (GvHD). For more information, visit the company’s website at www.endonovo.com